Canaccord Genuity Recommends AbbVie as Core Holding with $262 Target

Canaccord Genuity has identified pharmaceutical company AbbVie as a core holding, setting a price target of $262. The firm highlights AbbVie's potential as a durable compounder in the biopharma sector.